Cadrenal Therapeutics (CVKD) Competitors $14.75 -0.28 (-1.86%) As of 02:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CVKD vs. COYA, SGMT, IVVD, MGNX, BDTX, CTNM, ENTX, KYTX, OPTN, and HLVXShould you be buying Cadrenal Therapeutics stock or one of its competitors? The main competitors of Cadrenal Therapeutics include Coya Therapeutics (COYA), Sagimet Biosciences (SGMT), Invivyd (IVVD), MacroGenics (MGNX), Black Diamond Therapeutics (BDTX), Contineum Therapeutics (CTNM), Entera Bio (ENTX), Kyverna Therapeutics (KYTX), OptiNose (OPTN), and HilleVax (HLVX). These companies are all part of the "pharmaceutical products" industry. Cadrenal Therapeutics vs. Coya Therapeutics Sagimet Biosciences Invivyd MacroGenics Black Diamond Therapeutics Contineum Therapeutics Entera Bio Kyverna Therapeutics OptiNose HilleVax Coya Therapeutics (NASDAQ:COYA) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, community ranking, risk and media sentiment. Is COYA or CVKD more profitable? Coya Therapeutics' return on equity of -31.63% beat Cadrenal Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Coya TherapeuticsN/A -31.63% -27.76% Cadrenal Therapeutics N/A -142.95%-118.40% Does the MarketBeat Community believe in COYA or CVKD? Coya Therapeutics received 19 more outperform votes than Cadrenal Therapeutics when rated by MarketBeat users. Likewise, 92.86% of users gave Coya Therapeutics an outperform vote while only 87.50% of users gave Cadrenal Therapeutics an outperform vote. CompanyUnderperformOutperformCoya TherapeuticsOutperform Votes2692.86% Underperform Votes27.14%Cadrenal TherapeuticsOutperform Votes787.50% Underperform Votes112.50% Which has more risk and volatility, COYA or CVKD? Coya Therapeutics has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Comparatively, Cadrenal Therapeutics has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500. Do analysts prefer COYA or CVKD? Coya Therapeutics currently has a consensus target price of $17.00, suggesting a potential upside of 193.86%. Cadrenal Therapeutics has a consensus target price of $32.00, suggesting a potential upside of 117.61%. Given Coya Therapeutics' higher probable upside, equities research analysts clearly believe Coya Therapeutics is more favorable than Cadrenal Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Cadrenal Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation and earnings, COYA or CVKD? Coya Therapeutics has higher revenue and earnings than Cadrenal Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoya Therapeutics$3.69M26.26-$7.99M-$1.07-5.41Cadrenal TherapeuticsN/AN/A-$8.36M-$9.26-1.59 Do institutionals & insiders hold more shares of COYA or CVKD? 39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 9.8% of Coya Therapeutics shares are owned by insiders. Comparatively, 48.6% of Cadrenal Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media refer more to COYA or CVKD? In the previous week, Coya Therapeutics had 14 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 19 mentions for Coya Therapeutics and 5 mentions for Cadrenal Therapeutics. Coya Therapeutics' average media sentiment score of 0.53 beat Cadrenal Therapeutics' score of -0.20 indicating that Coya Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coya Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Cadrenal Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryCoya Therapeutics beats Cadrenal Therapeutics on 12 of the 15 factors compared between the two stocks. Get Cadrenal Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CVKD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVKD vs. The Competition Export to ExcelMetricCadrenal TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.93M$6.47B$5.31B$8.31BDividend YieldN/A2.64%5.20%4.10%P/E Ratio-2.208.5926.6919.58Price / SalesN/A257.78393.58120.51Price / CashN/A65.8538.2534.62Price / Book1.666.396.744.47Net Income-$8.36M$143.98M$3.23B$248.32M7 Day Performance-5.13%-0.06%0.01%-1.26%1 Month Performance-12.89%1.64%8.69%10.52%1 Year PerformanceN/A-0.73%18.36%8.53% Cadrenal Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVKDCadrenal Therapeutics2.7764 of 5 stars$14.75-1.9%$32.00+116.9%N/A$29.01MN/A-2.214News CoverageAnalyst RevisionCOYACoya Therapeutics2.09 of 5 stars$6.14+1.5%$17.00+176.9%-29.6%$102.69M$3.55M-9.456Analyst DowngradeAnalyst RevisionSGMTSagimet Biosciences1.5615 of 5 stars$3.31+1.5%$22.40+576.7%-32.9%$101.53M$2M-2.318Gap DownIVVDInvivyd2.8972 of 5 stars$0.84+29.7%$7.52+797.2%-64.8%$100.50M$25.38M-0.43100Gap UpMGNXMacroGenics3.6681 of 5 stars$1.59+11.2%$7.43+367.2%-66.4%$100.31M$148.34M-1.01430News CoverageAnalyst ForecastAnalyst RevisionBDTXBlack Diamond Therapeutics3.1684 of 5 stars$1.75+6.7%$14.60+734.3%-59.1%$99.19MN/A-1.3290News CoveragePositive NewsAnalyst UpgradeGap UpCTNMContineum Therapeutics2.4087 of 5 stars$3.83-1.0%$23.75+520.1%-75.3%$99.09M$50M-0.7831ENTXEntera Bio1.9571 of 5 stars$2.15flat$10.00+365.1%-17.3%$97.66M$181,000.00-8.2720News CoveragePositive NewsGap UpKYTXKyverna Therapeutics2.1768 of 5 stars$2.21+4.7%$18.33+729.6%-81.5%$95.51M$7.03M-0.6496News CoverageAnalyst RevisionGap UpOPTNOptiNose3.1658 of 5 stars$9.42+0.3%$9.00-4.5%N/A$95.09M$78.23M-2.24190News CoverageAnalyst RevisionHLVXHilleVax2.4114 of 5 stars$1.89-0.5%$3.00+58.7%-86.8%$94.77MN/A-0.6120News Coverage Related Companies and Tools Related Companies COYA Competitors SGMT Competitors IVVD Competitors MGNX Competitors BDTX Competitors CTNM Competitors ENTX Competitors KYTX Competitors OPTN Competitors HLVX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CVKD) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cadrenal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cadrenal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CVKD Stock Free CVKD Stock Alerts